Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21827557 | 1.00 | CYP2A13 (0.41) | CYP2A13SMN1; SMN2LMNACYP2C9ALDH1A1 | |
| SCHEMBL3634647 | 1.00 | CYP2A13 (0.41) | CYP2A13SMN1; SMN2LMNACYP2C9ALDH1A1 | |
| SCHEMBL12014348 | 0.84 | LMNA (0.43) | CYP2A13SMN1; SMN2LMNACYP2C9ALDH1A1 | |
| SCHEMBL8989805 | 0.81 | SMN1; SMN2 (0.43) | CYP2A13SMN1; SMN2LMNACYP2C9ALDH1A1 | |
| SCHEMBL1699949 | 0.78 | SMN1; SMN2 (0.44) | CYP2A13SMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL1699950 | 0.78 | SMN1; SMN2 (0.44) | CYP2A13SMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL22180112 | 0.77 | CYP2A13 (0.48) | CYP2A13SMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL19936626 | 0.77 | CYP2A13 (0.48) | CYP2A13SMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL22180343 | 0.77 | CYP2A13 (0.48) | CYP2A13SMN1; SMN2ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL22179872 | 0.77 | CYP2A13 (0.48) | CYP2A13SMN1; SMN2ALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305116-A1 | Compounds Comprising a Cyclobutoxy Group | UCB PHARMA, S.A. (BE) | 2010-12-02 | — | — | US | claimed |
| EP-2146980-A2 | HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma S.A. (BE) | 2010-01-27 | — | — | EP | claimed |
| WO-2008128919-A2 | HISTAMINE H3 RECEPTOR LIGANDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA S.A. (BE) | 2008-10-30 | — | — | WO | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2024256554-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-12-19 | — | — | WO | disclosed |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-3511327-B1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | LANOVA MEDICINES LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3511327-B1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | LANOVA MEDICINES LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3860980-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-08-11 | — | — | EP | disclosed |
| US-20190248772-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | SHANGHAI XIANGJIN BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| US-20190248772-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | SHANGHAI XIANGJIN BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3511327-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | Shanghai Xiangjin Biotechnology Co., Ltd (CN) | 2019-07-17 | — | — | EP | disclosed |
| EP-3511327-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | Shanghai Xiangjin Biotechnology Co., Ltd (CN) | 2019-07-17 | — | — | EP | disclosed |
| CN-107235896-A | Tyrosine kinase inhibitor and application thereof | 上海翔锦生物科技有限公司 | 2017-10-10 | — | — | CN | disclosed |
| US-20100305116-A1 | Compounds Comprising a Cyclobutoxy Group | UCB PHARMA, S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA S.A. (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-2238144-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma, S.A. (BE) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009092764-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305116-A1 | Compounds Comprising a Cyclobutoxy Group | HMGCR, TECR, CYP4A11 | CYP2A13 178/4885SMN1; SMN2 3586/4885LMNA 1421/4885 |
| US-20190248772-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | KDR, FLT1, MET | CYP2A13 965/4885SMN1; SMN2 4375/4885LMNA 3928/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | CYP2A13 4326/4885SMN1; SMN2 4102/4885LMNA 3056/4885 |
| US-11612606-B2 | 8-aminoisoquinoline compounds and uses thereof | PHKG1, MAP4K5, HIPK1 | CYP2A13 3858/4885SMN1; SMN2 3099/4885LMNA 3219/4885 |
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | CYP11B2, CYP11B1, CYP4B1 | CYP2A13 79/4885SMN1; SMN2 3381/4885LMNA 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.